Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17653926 | 0.82 | RXRA (0.50) | GAAALDH1A1LMNAMAPTHPGD | |
| SCHEMBL7714782 | 0.82 | ALDH1A1 (0.43) | GAAALDH1A1GFERPDK2CYP4F2 | |
| SCHEMBL2642622 | 0.81 | ALDH1A1 (0.49) | GAAALDH1A1GFERPDK2CYP4F2 | |
| SCHEMBL2126752 | 0.81 | ALDH1A1 (0.60) | GAAALDH1A1GFERPDK2CYP4F2 | |
| SCHEMBL20214473 | 0.81 | GAA (0.49) | GAAALDH1A1GFERPDK2CYP4F2 | |
| SCHEMBL8467020 | 0.81 | ALDH1A1 (0.49) | GAAALDH1A1GFERPDK2CYP4F2 | |
| SCHEMBL20576241 | 0.79 | ALDH1A1 (0.48) | GAAALDH1A1GFERPDK2CYP4F2 | |
| SCHEMBL1780814 | 0.79 | IDO1 (0.53) | GAAALDH1A1GFERPDK2CYP4F2 | |
| SCHEMBL2645838 | 0.78 | ALDH1A1 (0.49) | GAAALDH1A1GFERPDK2CYP4F2 | |
| SCHEMBL14420080 | 0.78 | ALDH1A1 (0.49) | GAAALDH1A1GFERPDK2CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2455105-A2 | Bombesin analogues | Bayer Pharma Aktiengesellschaft (DE) | 2012-05-23 | — | — | EP | disclosed |
| EP-2289564-A2 | Derivatives of aniline as precursors for F18-labeling | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-03-02 | — | — | EP | disclosed |
| EP-2279759-A2 | Compounds and methods for 18F labeled agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-02-02 | — | — | EP | disclosed |
| US-20080292548-A1 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | Lantheus Biosciences Ltd. (GB) | 2008-11-27 | — | — | US | disclosed |
| EP-1985624-A2 | Single step method of radiofluorination of biologically active compounds or biomolecules | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008028688-A2 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292548-A1 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | QPCT, GBA2, GBA1 | GAA 37/4885ALDH1A1 2019/4885GFER 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.